Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 18

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 18
---
)
for a proposed reverse merger (the “COVIRIX “Proposed Transaction”). However, on September 21, 2024, COVIRIX withdrew
from the Proposed Transaction, as such the Proposed Transaction was terminated with no cost to the Company. On December
11, 2024, NewGenIvf also announced its entry into a binding term sheet with European Wellness Investment Holdings Limited (“EWIHL”)
for a proposed reverse merger (“EWIHL Proposed Transaction”), completion of which was subject to, among other conditions,
the completion of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing. On March 31, 2025, NewGenIvf
terminated the term sheet for the EWIHL Proposed Transaction as EWIHL had failed to produce certain draft audited financials, which were
specifically required in the term sheet.

On February 28, 2025, NewGenIvf
completed its acquisition of the MicroSort technology from Genetics & IVF Institute, Inc. (“GIVF”). Pursuant to a Purchase
Agreement dated January 21, 2025 between NewGenIvf and GIVF (“Purchase Agreement”), NewGenIvf purchased all of the Assets
(as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort Business (as
defined in the Purchase Agreement) from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary
Shares (equivalent to 12,500 Class A Ordinary Shares post Second Reverse Stock Split) (“MicroSort Acquisition”).

White Lion Transaction

On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC (“White
Lion”) and a related Registration Rights Agreement (the “RRA”). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars ($100,000,000)
in aggregate gross purchase price of newly issued Class A Ordinary Shares, with an automatic increase to Three Hundred Million Dollars
($300,000,000) upon any substantial M&A or Material Transaction (as defined in the White Lion Purchase Agreement) and a further option
to increase to Five Hundred Million Dollars ($500,000,000) after Two Hundred and